Adaptimmune reports Phase I safety data for TCR therapy

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported safety data from eight evaluable patients receiving 90-100 million cells of its MAGE-A10 SPEAR T cell therapy in two open-label Phase I trials to treat cancer. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The therapy comprises T cells modified to express TCRs targeting melanoma-associated antigen A10 (MAGEA10).

One trial is enrolling patients with stage IIIb or IV non-small cell lung cancer (NSCLC) who have failed at least one platinum-containing therapy, and the other is enrolling patients with inoperable or metastatic urothelial cancer, melanoma or squamous cell carcinoma of the head and neck (SCCHN) cancer who progressed after standard of care...